AUS
NZ
UK
CA
USA
IND
Adia Med Inc. (OTCQB: ADIA), a clinical-stage regenerative medicine firm headquartered in Winter Park, Florida, announced on July 15, 2026, the launch of its revamped corporate website at www.adiamed.com. This website update comes after the company’s recent rebranding from Adia Nutrition Inc. to Adia Med Inc., a strategic decision aimed at better reflecting its primary focus on regenerative medicine, stem cell therapies, and advanced biologics. The enhanced digital platform is designed to increase transparency and accessibility for patients, healthcare providers, media, and investors as the company progresses with its clinical programs. Visitors to the former site, www.adianutrition.com, are now automatically redirected to the new Adia Med website.
Key Highlights
- Adia Med Inc. (OTCQB: ADIA), previously known as Adia Nutrition Inc., is a clinical-stage regenerative medicine company based in Winter Park, Florida.
- On July 15, 2026, the company launched a redesigned corporate website at www.adiamed.com, with ongoing enhancements still underway.
- The website launch follows the company’s recent name change to better align with its focus on regenerative medicine, stem cell therapies, and advanced biologics.
- Investors and stakeholders should monitor for further updates as Adia Med advances its clinical programs and expands its nationwide clinic network.
Adia Med Inc. Rebranding Highlights Commitment to Regenerative Medicine
Adia Med Inc. officially transitioned from Adia Nutrition Inc. to Adia Med Inc., marking a strategic shift to align its brand with core operations focused on regenerative medicine, stem cell therapies, and advanced biologics. This change signifies a clear departure from its previous nutrition-centered identity.
The rebranding and website relaunch are coordinated efforts to communicate the company’s updated direction. CEO Larry Powalisz stated, "Following our name change, we wanted a digital presence that better reflects who we are today." Specific timelines or regulatory details regarding the name change were not disclosed in this release.
New Website at www.adiamed.com Establishes Central Digital Platform
The newly launched website at www.adiamed.com serves as the company’s main digital hub, featuring dedicated sections on clinical studies, stem cell therapies, and aesthetic services. The platform also includes, or plans to include, media coverage, press materials, podcasts, video interviews, clinical case studies, investor resources, regulatory filings, company news, and educational content.
The website redesign is an ongoing project, with continuous updates and improvements expected. The previous domain, www.adianutrition.com, now redirects users to the updated site, consolidating the company’s online presence under its new brand.
CEO Larry Powalisz Emphasizes Enhanced Stakeholder Communication
CEO Larry Powalisz highlighted the website’s role in improving engagement, saying, "The new site provides clearer and more comprehensive information about our clinical studies, stem cell therapies, aesthetics offerings, and corporate developments, making it easier for patients, healthcare professionals, media, and investors to engage with us."
This platform is designed to serve multiple audiences simultaneously, enhancing transparency and accessibility as the company progresses with clinical and growth initiatives. No specific engagement or performance metrics were provided.
Adia Med’s Stem Cell Products and Lab Division: AdiaVita and AdiaLink
According to the company, Adia Med specializes in stem cell and regenerative products, including AdiaVita and AdiaLink, marketed through its lab division, Adia Labs LLC. The lab division is expanding to include insurance-billable wound care products, identified as a growth segment within its portfolio.
Adia Labs LLC operates a separate website at www.adialabs.com. The addition of insurance-billable wound care products introduces a recurring revenue stream supported by payers alongside existing product sales. The company did not disclose revenue figures, sales volumes, or expansion timelines for Adia Labs LLC.
Nationwide Expansion of Adia Med Clinics Offering Orthopedic and Wound Repair Services
Adia Med’s clinic network is growing nationwide, focusing on orthopedic care, pain management, and wound repair. These clinics provide advanced regenerative treatments such as stem cell therapies, platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT).
The clinic expansion forms a key part of the company’s business model alongside its lab and product sales divisions. Details regarding the number of clinics, target markets, or capital needs were not disclosed. Investors may note the comprehensive service offerings across orthopedic, aesthetic, and wound care categories.
Diversified Revenue Model Includes Service Fees, Product Sales, Insurance Billing, and Equity Interests
Adia Med generates revenue from various sources: clinical service fees, product sales, equity stakes in related businesses, and insurance billing for healthcare treatments. This multi-channel approach captures income from both direct clinical services and proprietary regenerative products via Adia Labs LLC.
The company holds an equity investment in Cement Factory LLC, a nutrition and supplement firm aligned with its health and wellness values. Financial details regarding this stake or segment revenues were not disclosed. This diversified revenue structure reflects a complex but multi-faceted business model.
Website Designed to Serve Patients, Healthcare Providers, Media, and Investors
The new website targets four primary audiences: patients, healthcare professionals, media, and investors. Dedicated sections for investor information, regulatory filings, clinical case studies, and media materials consolidate communications within a single platform.
Offering podcasts, video interviews, and press content alongside clinical and corporate information positions the site as a dynamic resource hub. The release notes the project is ongoing, with some sections live and others planned. OTCQB listing details and regulatory filings are included within the investor section.
Forward-Looking Statements and Regulatory Information for OTCQB-Listed ADIA
Trading on the OTCQB under ticker ADIA, Adia Med includes a standard safe harbor statement noting that forward-looking statements involve risks and uncertainties, with actual results possibly differing materially. The company disclaims any obligation to update these statements.
References to clinical advancements, clinic expansion, and product development are forward-looking. Additional risk factors are available in filings with the U.S. Securities and Exchange Commission and OTC Markets, Inc. No specific SEC filing details or financial results were provided.
Multiple Online Platforms Including adialabs.com and cementfactory.co
Besides www.adiamed.com, Adia Med operates www.adialabs.com for its lab division and www.cementfactory.co for its affiliated nutrition and supplement investment, Cement Factory LLC. The company maintains a social media presence on Twitter (X) under @ADIA_MED.
This multi-site online approach reflects the segmented business model, separating clinical and corporate branding from laboratory and wellness investments. The new corporate website serves as the main entry point for stakeholders. No web traffic or performance data was disclosed.
Adia Med’s Position in the Regenerative Medicine Sector
Adia Med Inc. is a clinical-stage regenerative medicine company focused on therapies that repair or regenerate human cells, tissues, and organs. Its portfolio includes stem cell therapies, PRP treatments, TPE, and aHSCT, placing it within a specialized healthcare and biosciences segment subject to regulatory oversight and FDA-approved lab protocols.
Based in Winter Park, Florida, with nationwide clinic expansion, Adia Med operates within the growing U.S. regenerative medicine market. The company did not disclose clinical trial statuses, patient outcomes, or regulatory milestones. Stakeholders should consider the inherent development and regulatory risks typical for clinical-stage companies in this sector, as noted in the company’s safe harbor disclosures.
